CHEMOTHERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Chemotherapy Market, By Drugs (Alkylating agents, Antimetabolites, Anti-tumor Antibiotics, and Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Liver Cancer, and Others), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In May 2023, CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche’s PD-L1 checkpoint inhibitor, along with chemotherapy (capecitabine and oxaliplatin) received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) for the first-line combination treatment of gastric cancer.
For instance, in January 2023, Merck & Co., Inc., a global pharmaceutical company, announced that the U.S. Food and Drug Administration (U.S. FDA) had approved KEYTRUDA (pembrolizumab) as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC). Additionally, the development of targeted therapies that have fewer side effects poses a threat to chemotherapy drug sales over the long run.
In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa), manufactured by Seagen Inc., a biotechnology company, in combination with trastuzumab for treatment of RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy